<DOC>
	<DOCNO>NCT00001509</DOCNO>
	<brief_summary>A body preclinical data provide strong rationale evaluate combination IFN-alpha retinoic acid . The two drug different mechanism action , use combination , show enhanced activity adult pediatric tumor cell line . The combination antiproliferative differentiation induce effect retinoids together antiproliferative , immunostimulatory differentiation-potentiating effect IFN-alpha warrant clinical investigation combination treatment refractory pediatric malignancy .</brief_summary>
	<brief_title>A Phase II Trial All-Trans-Retinoic Acid Combination With Interferon-Alpha 2a Children With Recurrent Neuroblastoma Wilms ' Tumor</brief_title>
	<detailed_description>A body preclinical data provide strong rationale evaluate combination IFN-alpha retinoic acid . The two drug different mechanism action , use combination , show enhanced activity adult pediatric tumor cell line . In pediatric phase I trial administer ATRA 3 consecutive days/week repeat weekly , AUC ATRA decrease day 1 day 3 drug administration return day 1 level begin subsequent week . This intermittent schedule ATRA administration allow exposure relatively high plasma concentration ATRA repetitive basis . The combination ATRA/IFN-alpha 2a demonstrate clinical activity pediatric phase I trial neuroblastoma Wilms ' tumor . The combination antiproliferative differentiation induce effect retinoids together antiproliferative , immunostimulatory differentiation-potentiating effect IFN-alpha warrant clinical investigation combination treatment refractory pediatric malignancy .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Wilms Tumor</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>AGE : All patient must less equal 21 year age . PERFORMANCE STATUS : Patients ECOG performance status 0 , 1 , 2 , life expectancy least 8 week . HISTOLOGIC DIAGNOSIS : Patients follow diagnosis , confirm appropriate histologic examination , eligible study : neuroblastoma Wilms ' tumor . MEASURABLE DISEASE : Patients must measurable disease . Patients evaluable disease ( i.e. , limit positive bone scan bone marrow ) eligible bone involvement measurable alternative imaging modality ( MRI , CT , plain film ) . PROGRESSIVE DISEASE : Patients must evidence progressive disease follow prior therapy . HEMATOLOGIC FUNCTION : Patients evaluable hematologic toxicity enrol onto study . Patients without bone marrow involvement tumor , history BMT , prior craniospinal pelvic radiation , consider evaluable hematologic toxicity . Patients evaluable hematologic toxicity must adequate bone marrow function ( defined peripheral absolute granulocyte count great 1500/mm ( 3 ) , hemoglobin great 8.0 gm % platelet count great 100,000/mm ( 3 ) ) . HEPATIC FUNCTION : Patients must adequate liver function ( bilirubin le 2.0 mg % ; SGPT le 2 time normal ) . RENAL FUNCTION : Patients must adequate renal function define creatinine clearance great equal 70 ml/min/1.732 serum creatinine base age follow : equal less 5 year old : maximum serum creatinine 0.8 ; old 5 equal less 10 : 1.0 ; old 10 equal less 15 : 1.2 ; old 15 : 1.5 . RECOVERY FROM PRIOR THERAPY : Patients must recover toxic effect prior therapy , must chemotherapy minimum two week prior entry onto protocol ( minimum six week prior nitrosoureas ) . INFORMED CONSENT : All patient legal guardian must sign document inform consent indicate awareness investigational nature risk study . No history CNS malignant disease , hydrocephalus , pseudotumor cerebri . No history treatment 13cis retinoic acid within prior three month . Women childbearing potential must pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 1999</verification_date>
	<keyword>Differentiation</keyword>
	<keyword>N-myc Expression</keyword>
	<keyword>Retinoid</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>Trk Expression</keyword>
</DOC>